GLUE Stock — Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. (GLUE)

Updated October 16, 2026.

GLUE is a Stock. Total return is -54.0% over the past 5.3 years, 146.6 points behind SPY at 92.6%.

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing small molecule precision medicines designed to selectively degrade disease-causing proteins using molecular glue degrader technology. The company's pipeline spans oncology, immunology, inflammation, and other therapeutic areas, with programs in development through collaborations with major pharmaceutical partners including Roche and Novartis. As a pre-revenue biotech company, it does not currently distribute income to shareholders.

GLUE performance versus SPY

Price and return data through 2026-10-16.

Total return is -54.0% over the past 5.3 years, 146.6 points behind SPY at 92.6%. Over the past year its total return — price change plus distributions reinvested — is -5.5%. Its deepest 1-year drawdown was 61.5%.

GLUE key facts

Asset type

Stock

Asset class

Equity

Inception date

06/24/2021

Distribution frequency

None

Last close

$9.74 (as of 2026-10-16)

Market cap

$830,952,526

Average volume

885410.0

Beta

1.369

Payout ratio

0.0%

Forward P/E

10.02

EPS

$-1.75

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GLUE risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 61.5%.

Who may consider GLUE — and who may not

It is a weaker fit for investors who need monthly cash flow (GLUE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on GLUE

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions